Abstract Purpose: Epidermal growth factor (EGF) plays a critical role in cancer. A polymorphism in the EGF gene (EGF+61) may influence its expression and contribute to cancer predisposition and aggressiveness. In the present study, we aimed to elucidate the role of EGF+61in glioma susceptibility and prognosis. Experimental Design: A case-control study involving197 glioma patients and 570 controls was done. Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95 % confidence intervals (95 % CI). False-positive report probability was also assessed. The luciferase reporter gene assay was used to ascertain the functional consequences of this polymorphism. Results: Corroborating the univariate analysis, the multivariate model showed that the G allele conferred higher risks for gliomas (OR, 1.32; 95% CI, 1.04-1.67), glioblastomas (OR, 1.47; 95% CI, 1.02-2.10), and oligodendrogliomas (OR, 1.55; 95% CI, 1.07-2.23). The GG genotypes were associated with increased risk for gliomas (OR, 1.71; 95% CI, 1.07-2.73), glioblastomas (OR, 2.03; 95% CI, 1.02-4.05), and oligodendrogliomas (OR, 2.72; 95% CI, 1.18-6.28). In addition, the AG+GG genotypes were associated with higher risk for gliomas (OR, 1.52; 95% CI, 1.03-2.23) and oligodendrogliomas (OR, 2.80; 95% CI, 1.35-5.79). No significant association was observed between the EGF+61polymorphism and glioblastoma or oligodendroglioma patients' overall survival. The luciferase reporter gene assay exhibited a significant increased promoter activity for the G variant compared with the reference A allele. Conclusions: These findings support the role of the EGF+61 polymorphism as a susceptibility factor for development of gliomas and show its implication on EGF promoter activity.
oligoastrocytic), the major histologic types. According to the WHO, gliomas can be classified into four grades of malignancy (3) . Despite all advances in neurosurgery and adjuvant radiotherapy and chemotherapy, glioma patients' prognosis is dismal (4) . Survival of glioblastoma patients, the most common and aggressive (WHO grade 4) form of glioma in adults, is very poor, with median survival times ranging from f10 months in patients younger than 65 years to 3.5 months for those older than 65 years (5) .
Deregulation of growth signaling pathways constitute a hallmark of cancer (6) . Epidermal growth factor (EGF) encodes a ligand for the EGF receptor (EGFR). Upon EGFR activation, a cascade of intracellular signaling pathways is initiated that will ultimately influence cell proliferation, inhibition of apoptosis, and differentiation (6 -9) . Alterations of EGF/EGFR signaling occur frequently in gliomas by several mechanisms, including autocrine/paracrine stimulation loops, EGFR gene amplification, and activating mutations (e.g., EGFRvIII). These abnormalities are associated with glioma growth, invasion, and malignancy (3, 8, 10) . Therefore, EGF plays a key role in the gliomagenesis (9, 10) .
Besides somatic molecular alterations, a growing body of evidence has been demonstrating that common germ line polymorphisms may play a role in cancer risk and can influence tumor progression, prognosis, and therapies response (11 -15) . Shahbazi et al. (16) identified a single-nucleotide polymorphism in the 5 ¶ untranslated region of the EGF gene (an A-to-G variant found 61 bp downstream of the EGF transcription start site-EGF+61 polymorphism). In this study, the authors found that the GG genotype was significantly associated with risk of malignant melanoma and that cells from individuals with the AA genotype produced significantly less EGF than cells from individuals with either the AG or GG genotypes. However, later independent studies have reported some conflicting results (17 -22) . Besides melanomas, Bhowmick et al. (23) showed a relationship between this functional polymorphism and the risk and aggressiveness of glioblastomas. By studying 42 American patients, they found that both frequencies of G allele and GA or GG genotypes were significantly higher in glioblastoma patients than in healthy individuals. Additionally, patients with the GA or GG genotype had a significant shorter progression-free survival than those with the AA genotype (23) .
Considering the paramount role of EGF/EGFR signaling in gliomas and the potential implication of EGF+61 in glioblastoma development, we proposed to clarify the significance of this genetic polymorphism in the glioma susceptibility. We did a case-control study of 197 glioma patients and 570 cancer-free controls from Portugal. Associations of EGF+61 genotypes with tumor risk and patient prognosis were assessed. In addition, the functional consequences of the EGF+61 genetic variants were evaluated by luciferase reporter analysis.
Materials and Methods
Study population. In this case-control study, we enrolled 197 patients gliomas, diagnosed at Hospital S. João, Porto, and Hospital S. Marcos, Braga, Portugal. All new consecutive cases of glioma patients, submitted to craniotomy with available tumor material, were eligible, which represented f60% of patient seen in the two hospitals during the period of January 1990 to December 2004. Tumors were classified according to WHO (3) , and clinicopathologic features are summarized in Table 1 . The control group was randomly selected from blood donors at Hospital S. Marcos, Braga, and it included 570 cancer-free individuals. All patients and controls were from Northwest Portugal and of Caucasian ethnic background. The procedures followed in the present study were in accordance with the institutional ethical standards. All the samples enrolled in the present study were unlinked and unidentified from their donors.
Genotyping. Cancer patients' genomic DNA was extracted from formalin-fixed, paraffin-embedded tumor tissue, as previously described (24) . No peripheral blood DNA was available from the majority of glioma patients. DNA from control individuals was extracted from leukocytes of blood samples by proteinase K/chloroform/isopropanol treatment (25) . The purified DNA was used to determine the genotypes for the EGF+61 polymorphism, using PCR-RFLP methods as previously described (23) . Briefly, the EGF region from nucleotide positions -78 to +164 was amplified by PCR, producing a 242-bp fragment. After restriction of the PCR products with 2 units of AluI (Fermentas) for 16 h at 37jC, 61G alleles were distinguished from 61A alleles by visualization of a single 193-bp fragment instead of 91 and 102 bp fragments on a 3% agarose gel stained with ethidium bromide.
Plasmid construction. To study the effect on the promoter activity of the EGF+61 A-G polymorphism, a 756-bp fragment between nucleotides -552 to +204 containing either the A (wild type) or the variant allele (G) was initially amplified from genomic DNA (isolated from subjects homozygous either for the A or G allele) with EGF-specific primers incorporating MluI and HindIII restriction sites (5 ¶-ACGCGT-CATACTGTATCTCTTCATTTGG-3 ¶ and 5 ¶-AAGCTTTGGAAGCCAGTAA-GAAATACC-3 ¶, respectively). The two purified PCR products were subcloned into pCR2.1 vector (Invitrogen) to obtain plasmid pCR2.1-EGF+61A or pCR2.1-EGF+61G. The DNA sequences of inserts were verified by sequencing using M13 primers (Invitrogen). The two promoter sequences had no sequence differences other than the +61. The pCR2.1-EGF plasmids containing +61A or +61G were then digested with MluI and HindIII overnight at 37jC and subcloned into the pGL3-Basic vector (Promega Corporation), upstream of the firefly luciferase reporter gene, to generate pGL3-EGF+61A and pGL3-EGF+61G, respectively. All constructs were checked by direct sequencing using GLprimer2 and RVprimer3 (Promega) on an ABI PRISM 3100 Genetic Analyser sequencer (Applied Biosystems).
Cell culture, transfection, and luciferase assay. U251 glioma cells (kindly provided by Dr. Joseph Costello, University of California, San Francisco, San Francisco, CA) and MDA-MB-435 breast carcinomaderived cells were grown in 50% DMEM and 50% Ham's F12 medium supplemented with 10% fetal bovine serum and 1% of penicillin and streptomycin (Life Technologies), in a humidified atmosphere at 37jC with 5% CO 2 . Transient transfection experiments were done using the LipofectAMINE reagent (Invitrogen). Briefly, cells were seeded in DMEM at 5.0 Â 10 5 per well in six-well plates. Transfections were done the next day by mixing 1 Ag of the pGL3 construct of interest and 0.5 Ag of the control h-galactosidase -expressing vector, with Lipofect-AMINE 2000 (Invitrogen; LipofectAMINE/DNA ratio of 3:1) in 6 mL of serum-free and antibiotic-free Opti-MEM (Invitrogen) medium. Cells were incubated with 1 mL of the transfection mixture for 16 h at 37jC. Total cell extracts were prepared after 48 h incubation at 37jC in DMEM using 1Â reporter lysis buffer (Promega), as described in the manufacturer's instruction manual. Twenty microliters of cell extract were mixed with 100 AL of luciferase assay reagent (Promega) to determine luciferase activity in a 1450 Microbeta luminescence counter (Wallac). The h-galactosidase activity was measured using 50 AL of cell extract. The luciferase activity of test plasmids is expressed as fold of induction of the test plasmid activity, after correction for transfection efficiency as measured by the h-galactosidase activity. Each assay was repeated in three independent experiments, including three replicates for the two constructs.
Statistical analysis. m 2 and nonparametric Wilcoxon-Mann Whitney tests were used to compare the frequency distribution of age, sex, and EGF+61 genotypes and alleles between cases and controls. Moreover, the m 2 test was used to verify that the observed allele distribution, in the control group, was in Hardy-Weinberg equilibrium. Odds ratios (OR) and 95% confidence intervals (95% CI) for the effect of EGF+61 variants on the risk for each glioma type were estimated by univariate and multivariate logistic regression analyses, adjusted for sex and age as 26) . Patient survival curves were assessed by the Kaplan-Meier method for glioblastoma and oligodendroglioma; the log-rank test was used to evaluate the differences. Statistical differences in luciferase reporter assays were assessed using a Student's t test. All statistical tests were two-sided, and significance was considered for P < 0.05. Data analysis was done using SPSS 14.0 software (SPSS, Inc.).
Results
EGF+61 and risk of glioma. We analyzed 197 glioma patients and 570 cancer-free control individuals to study associations between EGF+61 polymorphism and susceptibility to different types of gliomas. The distribution of EGF+61 allele frequencies in the control group was in Hardy-Weinberg equilibrium (P = 0.348). A summary of clinicopathologic features of the controls and cases is shown in Table 1 . The statistical analysis of age and sex distributions between control and case groups (gliomas, glioblastomas, and oligodendrogliomas) showed significant differences for all classes (P < 0.05).
When assessing the allele frequencies using univariate analysis (Table 2) , we found that the G allele was associated with higher risk for glioma (OR, 1.31; 95% CI, 1.04-1.65) and oligodendrogliomas (OR, 1.53; 95% CI, 1.06-2.19). Using AA genotype as reference, the OR analysis showed that both the GG and combined AG+GG genotypes were associated with increased risk for glioma (OR, 1.68; 95% CI, 1.07-2.65 for GG; OR, 1.52; 95% CI, 1.04-2.22 for AG+GG; Table 2 ). In oligodendroglioma cases, the AG, GG, and AG+GG genotypes were all associated with a higher risk (OR, 2.82; 95% CI, 1.33-5.96 for AG; OR, 2.64; 95% CI, 1.15-6.06 for GG; OR, 2.76; 95% CI, 1.34-5.70 for AG+GG; Table 2 ). In addition, we stratified gliomas in astrocytomas (grades 2 and 3, n = 31). A protective effect was observed for AG genotype (OR, 0.33; 95% CI, 0.13-0.82; data not shown).
We further used a multivariate logistic regression model adjusted for sex and age as a continuous variable ( Table 3 ). The allelic analysis showed that the G allele was a risk factor for glioma (OR, 1.32; 95% CI, 1.04-1.67), oligodendroglial tumors (OR, 1.55; 95% CI, 1.07-2.23), and also glioblastoma (OR, 1.47; 95% CI, 1.02-2.10), when compared with the reference A variant. Consistent with the results obtained by the univariate analysis (Table 2) , the GG and combined AG+GG genotypes conferred increased risk for glioma (OR, 1.71; 95% CI, 1.07-2.73 for GG; OR, 1.52; 95% CI, 1.03-2.23 for AG+GG; Table 3 ). In oligodendrogliomas, the AG, GG, and AG+GG genotypes were all associated with higher risks (OR, 2.83; 95% CI, 1.33-6.02 for AG; OR, 2.72; 95% CI, 1.18-6.28 for GG; OR, 2.80; 95% CI, 1.35-5.79 for AG+GG; Table 3 ). The GG genotype increased by f2-fold the risk for glioblastoma (OR, 2.03; 95% CI, 1.02-4.05; Table 3 ) in this logistic regression model, whereas it failed to reach significance in the univariate analysis. The astrocytoma group (grades 2 and 3, n = 31), showed a protective effective for the AG genotype (OR, 0.32; 95% CI, 0.13-0.82; data not shown).
The calculation of FPRP showed that all of the abovementioned associations remained noteworthy (FPRP V 0.5) when a prior probability of association of z10% was considered, and all except two associations (glioblastoma and oligodendroglioma with GG genotype) remained noteworthy when a prior probability of association of z5% was considered (Table 4) . Concerning the astrocytoma group (grades 2 and 3), the only remaining noteworthy association was the AG genotype when a prior probability of association of z10% was considered (data not shown).
Survival and prognostic value of EGF+61. In glioblastoma (n = 44) and oligodendroglial tumors (n = 45) with available follow-up data, we also investigated the association between EGF+61 genotypes and overall survival time. Kaplan-Meier analysis did not show any statistically significant correlation between this polymorphism and glioblastoma patients' survival (P = 0.365). Similarly, no associations were found for oligodendroglial tumors (P = 0.459).
Functional role for the EGF+61 polymorphism by luciferase reporter assays. Having shown that the +61G allele of the EGF gene is associated with increased glioma risk, we sought to determine whether the EGF+61 A to G genetic variation has functional consequences. To accomplish this, we constructed two different pGL3-EGF+61 constructs for the +61A and +61G alleles (pGL3-EGF+61A and pGL3-EGF+61G, respectively) that were used to transiently transfect U251 glioma cells and MDA-MB-435 breast carcinoma-derived cells and assess their promoter activity. The average transcriptional activity of pGL3-EGF+61G was 1.65-and 1.53-fold higher than of pGL3-EGF+61A in U251 and MDA-MB-435 cancer cells, respectively, and these differences were statistically significant (P = 0.0020 and P = 0.0099, respectively; Fig. 1 ).
Discussion
Glioma carcinogenesis is a complex and still poorly understood process in which environmental and genetic factors cooperate with each other (27) . With the exception of therapeutic ionizing radiation, no other environmental factors are clearly associated with brain tumors risk (28 -31) . Recently, several studies have focused on the etiologic role of germ line genetic polymorphisms in glioma development and prognosis (32) . These studies included analysis of genes encoding proteins involved in DNA repair pathways (e.g., MGMT, XRCC7, and ERCC2; refs. 33 -35) , carcinogen metabolism (e.g., GST and CYP2D6; refs. 36 -38) , and the EGF gene (23) .
In this case-control study, we investigated the association of the EGF+61 polymorphism with glioma susceptibility and The results are representative of three independent experiments, including three replicates for both constructs. *, statistically significant difference using Student's t test (P = 0.0020 for U251cells; P = 0.0099 for MDA-MB-435 cells). (3, 39, 40) ; therefore, we have done a histologic stratification to elucidate more precisely the significance of the results. We found a significant association of the G variant with an increased risk of not only gliomas (OR, 1.35) but also glioblastomas (OR, 1.48) and oligodendroglial tumors (OR, 1.58). Notably, we showed that individuals with EGF+61 GG genotype have approximately a 2-fold increased risk for glioma and glioblastoma and approximately a 3-fold risk for oligodendroglial tumors. Our data is in agreement with a previous study reporting a significant association between the G allele and the risk of developing glioblastoma (23) . The observed OR is likely to reflect a true association, as shown by the FPRP calculation. Bhowmick et al. (23) have observed a statistical association between the EGF+61 polymorphism and glioblastoma patients' progression-free survival. In the present series, no statistical association was found between the EGF+61 polymorphisms and glioblastoma and oligodendroglioma patients overall survival time. In the astrocytoma group (grades 2 and 3), we observed a protective effect associated with the AG genotype. This paradoxical association is most probably related to the rather small number of samples (n = 31) analyzed; however, supplementary studies are warranted to address this particular subtype of gliomas.
In the present work, the genotype analysis was evaluated in patient tumor tissue. Thus, we cannot exclude the existence of somatic alterations in the EGF locus (4q25), which would lead to misgenotyping. However, chromosomal abnormalities of the 4p25 region are infrequent in gliomas (3) . Moreover, in 20 glioma cases with available peripheral blood DNA, genotyping of both blood and tissue DNA was done with 100% concordance.
To clarify the biological consequences of this A to G polymorphism, we used a luciferase reporter gene assay in glial and breast tumor cells. In both tumor cell types, the activity of the EGF promoter containing the G allele was >1.5-fold higher than that of the A variant (reference). These results corroborate previous studies that reported higher levels of EGF mRNA expression and protein production by immunoassays associated with the presence of variant G (16, 23) . The association between the EGF+61 G allele and the increased production of EGF can have implications not only in gliomagenesis, as shown in this study, but also for patient response to the newly developed anti-EGFR therapies (41) . In fact, Zhang et al. (15) have recently reported a pilot study of molecular markers predictive of clinical outcome in metastatic colorectal patients treated with the single-agent cetuximab (anti-EGFR monoclonal antibody). Of the several genetic polymorphisms evaluated, only the combination of cyclin D1 (A870G) and EGF+61 polymorphisms was associated with patient survival (41) .
In conclusion, we have shown that the EGF+61 polymorphism is associated with an increased risk for gliomas, glioblastomas, and oligodendroglial tumors. In addition, using luciferase reporter assays, we showed the functional consequences attributable to this polymorphism in glioma and breast cancer cell lines. In the future, more studies are required to confirm our results and assess the potential of the EGF+61 polymorphism as a predictor of glioma patients' outcome and therapeutic responses to the newly approved anti-EGFR therapies (42) .
